These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 20607973

  • 1. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cojbasić I, Macukanović-Golubović L.
    Srp Arh Celok Lek; 2010; 138(5-6):305-8. PubMed ID: 20607973
    [Abstract] [Full Text] [Related]

  • 2. [Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
    Cojbasić I, Macukanović-Golubović L.
    Vojnosanit Pregl; 2011 Nov; 68(11):911-6. PubMed ID: 22191306
    [Abstract] [Full Text] [Related]

  • 3. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
    Cojbasić I, Macukanović-Golubović L.
    Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
    [Abstract] [Full Text] [Related]

  • 4. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.
    Blood; 2002 May 15; 99(10):3547-53. PubMed ID: 11986206
    [Abstract] [Full Text] [Related]

  • 5. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
    Med Oncol; 2004 May 15; 21(4):349-58. PubMed ID: 15579919
    [Abstract] [Full Text] [Related]

  • 6. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 15; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM.
    Blood; 2003 May 15; 101(10):3794-800. PubMed ID: 12560227
    [Abstract] [Full Text] [Related]

  • 8. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
    Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M.
    Clin Cancer Res; 2002 Jul 15; 8(7):2167-76. PubMed ID: 12114417
    [Abstract] [Full Text] [Related]

  • 9. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C, Grigg A, Szer J, Roberts A, Campbell L, Hoyt R, Lynch K, Juneja S.
    Clin Lab Haematol; 2003 Apr 15; 25(2):119-25. PubMed ID: 12641616
    [Abstract] [Full Text] [Related]

  • 10. Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital.
    Usman M, Kakepoto GN, Adil SN, Sajid R, Arain S, Khurshid M.
    J Pak Med Assoc; 2004 Jan 15; 54(1):17-20. PubMed ID: 15058636
    [Abstract] [Full Text] [Related]

  • 11. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.
    Blood; 2002 Jul 15; 100(2):435-41. PubMed ID: 12091333
    [Abstract] [Full Text] [Related]

  • 12. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
    Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J.
    Blood; 2004 Apr 15; 103(8):2873-8. PubMed ID: 15070658
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.
    Palanduz S, Bayrak A, Sirma S, Vural B, Cefle K, Ucur A, Ozturk S, Yenerel MN, Besisik SK, Yavuz S, Diz-Kucukkaya R, Sargin D, Nalcaci M, Pekcelen Y, Ozbek U.
    Genet Test Mol Biomarkers; 2009 Oct 15; 13(5):599-602. PubMed ID: 19814615
    [Abstract] [Full Text] [Related]

  • 14. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 15; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 15. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.
    Blood; 2006 Sep 15; 108(6):1835-40. PubMed ID: 16709931
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep 15; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 19. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
    Ueda K, Horiike S, Zen K, Misawa S, Taniwaki M.
    Leuk Lymphoma; 2006 Sep 15; 47(9):1967-9. PubMed ID: 17065015
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.